Kiniksa Pharmaceuticals, Ltd.

Kiniksa has an experienced team and numerous product-candidates in both clinical and preclinical development. The programs span a range of debilitating diseases with significant unmet medical need.We have a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions and have the potential to address multiple indication.We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines.

Bank Name Kiniksa Pharmaceuticals, Ltd.
Stock Exchange NASDAQ
Symbol KNSA
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
CEO Mr. Stephen Mahoney
Employees 47
Registered Year 2015